Profil de l'entreprise pour ULTIMOVACS AS DK1 Action
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Obtenez des informations actualisées de finAgent sur ULTIMOVACS AS DK1